Genextra Spa:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Genextra Spa - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10890
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genextra SpA (Genextra) is a therapies developing company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, INT- 777 for metabolic syndrome, mono therapy and diabetes, novel HDAC and HSP90 inhibitors for the treatment of cancer. It also provides mjPTP inhibitor and nanoparticles in gas phase to yields, among others. Genextra provides research in life science and to develop novel therapies and tools, among others. The company caters to entrepreneurs and financial institutions in partnership with leading scientists, among others. It operates through its subsidiaries located across Italy. Genextra is headquartered in Milan, Italy.

Genextra Spa – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genextra Spa, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Genextra Spa, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Genextra Spa, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
EryDel Raises USD32.4 Million in Venture Financing 10
EryDel Raises Additional USD16.23 million in Series B Financing 11
EryDel Raises US$20 Million In Series B Financing 12
Intercept Pharma Raises US$30 Million In Series C Financing 13
Partnerships 15
Intercept Pharma Extends Agreement with Target Pharma 15
Intercept Pharma Enters into Research Agreement with University of Perugia 16
Licensing Agreements 17
EryDel and Orphan Technologies Enter into Licensing Agreement 17
Equity Offering 18
Intercept Pharma Prices Private Placement of Shares for USD100 Million 18
Intercept Pharma Prices Public Offering of Shares for USD150 Million 20
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 22
Intercept Pharma Raises USD202 Million in Public Offering of Shares 24
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 26
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 28
Intercept Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$86 Million 30
Debt Offering 32
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 32
Genextra Spa – Key Competitors 34
Genextra Spa – Key Employees 35
Genextra Spa – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Genextra Spa, Pharmaceuticals & Healthcare, Key Facts 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genextra Spa, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genextra Spa, Deals By Therapy Area, 2012 to YTD 2018 8
Genextra Spa, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
EryDel Raises USD32.4 Million in Venture Financing 10
EryDel Raises Additional USD16.23 million in Series B Financing 11
EryDel Raises US$20 Million In Series B Financing 12
Intercept Pharma Raises US$30 Million In Series C Financing 13
Intercept Pharma Extends Agreement with Target Pharma 15
Intercept Pharma Enters into Research Agreement with University of Perugia 16
EryDel and Orphan Technologies Enter into Licensing Agreement 17
Intercept Pharma Prices Private Placement of Shares for USD100 Million 18
Intercept Pharma Prices Public Offering of Shares for USD150 Million 20
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 22
Intercept Pharma Raises USD202 Million in Public Offering of Shares 24
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 26
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 28
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$86 Million 30
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 32
Genextra Spa, Key Competitors 34
Genextra Spa, Key Employees 35
Genextra Spa, Subsidiaries 36

List of Figures
Genextra Spa, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genextra Spa, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Genextra Spa:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dar Al Takaful PJSC (DARTAKAFUL):企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Dar Al Takaful PJSC" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly follo …
  • Premier Gold Mines Limited:企業のM&A・事業提携・投資動向
    Premier Gold Mines Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Premier Gold Mines Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Abeinsa Ingenieria Y Construccion Industrial S.A.:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Abeinsa Ingenieria Y Construccion Industrial S.A." The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible f …
  • CoreRx Inc-製薬・医療分野:企業M&A・提携分析
    Summary CoreRx Inc (CoreRx) is a contract development manufacturing organization which provides a comprehensive range of drug development services. Its products portfolio includes oral, topical, liquids or parental, ophthalmic and combined medicines. The company offers a wide range of drug product d …
  • Merus NV (MRUS):企業財務及び戦略的SWOT分析
    Summary Merus NV (Merus) is a biotechnology company which discovers and develops human antibodies for the treatment of cancer. Its proprietary technology Biclonics are bispecific, full length human IgG antibodies which are used for the development of its lead candidate Biclonics. The company provide …
  • Equity Residential:企業の戦略・SWOT・財務分析
    SummaryEquity Residential - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Find …
  • Frasers Property Australia Pty Ltd:企業の戦略的SWOT分析
    Frasers Property Australia Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Wentworth Resources Ltd (WRL):石油・ガス:M&Aディール及び事業提携情報
    Summary Wentworth Resources Ltd (Wentworth) is an independent upstream oil and gas company. It conducts the exploration and development of oil and natural gas reserves. The company has producing gas assets in Tanzania, oil and gas exploration activities in both Mozambique and Tanzania. The company o …
  • IGas Energy PLC (IGAS):企業の財務及び戦略的SWOT分析
    Summary IGas Energy PLC (IGas Energy) is an oil and gas company that explores, develops and produces onshore oil and gas. The company provides services, such as unlocking the opportunity for Britain, extracting gas responsibly, and onshore oil and gas regulation. It extracts oil and gas trapped unde …
  • Perrigo Company Plc (PRGO)-医療機器分野:企業M&A・提携分析
    Summary Perrigo Company plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic and prescription pharmaceuticals, specialty pharmaceutical company, nutritional products, active pharmaceutic …
  • Triumph Aerostructures – Vought Aircraft Division(航空・防衛):企業概要、SWOT分析
    Summary SDI's "Triumph Aerostructures - Vought Aircraft Division: Aerospace and Defense - Company Profile and SWOT Report" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, busi …
  • Korea Alcohol Industrial Co., Ltd. (017890):企業財務及び戦略的SWOT分析
    Summary Korea Alcohol Industrial Co., Ltd. (Korea Alcohol) is a chemical company that manufactures and markets ethyl alcohol and others products. The company’s products comprise ethyl alcohol, esters, ethyl acetate, butyl acetate, ethylamines, acetaldehyde, electronic butyl acetate, mono ethylamine, …
  • Clovis Oncology Inc (CLVS):医療機器:M&Aディール及び事業提携情報
    Summary Clovis Oncology Inc (Clovis) is a biopharmaceutical company that acquires, develops and commercializes new anti-cancer agents. The company's development programs are targeted at specific cancer indications, combining personalized medicine with companion diagnostics. It develops and commercia …
  • Smruthi Organics Ltd (590046):企業財務及び戦略的SWOT分析
    Summary Smruthi Organics Ltd (Smruthi) is a manufacturer and distributor of bulk drugs, drug intermediates, fine chemicals and specialty chemicals. The company offers products which include amlodipine besilate, amisulpride, carbidopa, ciprofloxacin, diloxanide furoate, fenofibrate, metformin hydroch …
  • Mount Gibson Iron Limited (MGX):企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Mount Gibson Iron Limited" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly …
  • Epsilon Net S.A. (EPSIL):企業の財務及び戦略的SWOT分析
    Summary Epsilon Net S.A. (Epsilon) is an information technology company that provides business management software solution. The company’s products include taxation, accounting, payroll and pylon. Its taxation provides tax system 5 and tax system 5 estate. Epsilon’s accounting system offers extra ac …
  • DuSolo Fertilizers Inc. (DSF):企業の財務及び戦略的SWOT分析
    Summary DuSolo Fertilizers Inc. (DuSolo), formerly Eagle Star Minerals Corp is a mineral exploration company that provides phosphate-based fertilizers. The company acquires, explores and develops agro-mineral properties producing direct application natural fertilizers which is used in soil and yield …
  • Yungjin Pharm Ind. Co., Ltd. (003520):企業概要、財務及び戦略的SWOT分析
    Summary Yungjin Pharm. Co., Ltd (Yungjin) is a pharmaceutical company. The company develops, manufactures and distributes active pharmaceutical ingredients (API) and formulations. Its API products include cephalosporins and other general products. Yungjin also offers formulation products for various …
  • Monopar Therapeutics LLC:企業のM&A・提携動向(医療分野)
    Summary Monopar Therapeutics LLC (Monopar) is a biopharmaceutical company that focused on the development of orphan oncology compounds. The company’s lead compound, huATN-658, an anti-urokinase plasminogen activator receptor (uPAR) monoclonal antibody intended for the potential treatment of various …
  • Ausgrid-エネルギー分野:企業M&A・提携分析
    Summary Ausgrid is a state-owned electric corporation. It transmits, distributes, and retails electricity through transmission and distribution networks. The company also offers street lighting, tree trimming, combating graffiti, energy efficiency, installation and connection of small scale embedded …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆